ZAMIFENACIN
| 中文名称 | ZAMIFENACIN |
|---|---|
| 中文同义词 | 扎非那星;化合物 T17283 |
| 英文名称 | ZAMIFENACIN |
| 英文同义词 | (R)-3-(Benzhydryloxy)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)piperidine;Piperidine, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-3-(diphenylmethoxy)-, (3R)-;UK-76654 |
| CAS号 | 127308-82-1 |
| 分子式 | C27H29NO3 |
| 分子量 | 415.52 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 127308-82-1.mol |
| 结构式 |  |
ZAMIFENACIN 性质
| 储存条件 | Store at -20°C |
|---|
Zamifenacin (UK-76654) 是一种有效的肠道选择性毒蕈碱 M3 受体拮抗剂。Zamifenacin 可显着降低肠易激综合症的结肠蠕动。
Muscarinic M3 receptor
Zamifenacin exhibits moderate oral bioavailability (mouse 26%, rat 64%, dog 100%) and C
max
(mouse 92, rat 905, dog 416 ng/mL) following oral administration (mouse 13.2, rat 20 and, dog 5 mg/kg).
Zamifenacin exhibits terminal elimination half-lives (mouse 2.1, rat 6.0 and, dog 1.1 h) due to high plasma clearance (68, 35, and 39 mL/min/kg respectively) combined with large volumes of distribution (12.5, 19.0, and 3.5 L/kg respectively) following intravenous administration (mouse 5.3, rat 5.0 and, dog 1.0 mg/kg).
| Animal Model: | Male CDl mice (mean weight 23 g) |
| Dosage: | 5.3 mg/kg for i.v.; 13.2 mg/kg for oral (Pharmacokinetic Analysis) |
| Administration: | Intravenous administration and oral administration |
| Result: | Oral bioavailability (26%), C max (92 ng/mL), T 1/2 (2.1 h). |
| Animal Model: | Male and female CD rats (mean weight 210 g) |
| Dosage: | 5.0 mg/kg for i.v.; 20 mg/kg for oral (Pharmacokinetic Analysis) |
| Administration: | Intravenous administration and oral administration |
| Result: | Oral bioavailability (64%), C max (905 ng/mL), T 1/2 (6.0 h). |
| Animal Model: | Male and two female beagle dogs (13-16 kg) |
| Dosage: | 1.0 mg/kg for i.v.; 5 mg/kg for oral (Pharmacokinetic Analysis) |
| Administration: | Intravenous administration and oral administration |
| Result: | Oral bioavailability (100%), C max (416 ng/mL), T 1/2 (1.1 h). |